5'-(2-pyridylthio)-5'-deoxyadenosine | 5135-38-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 5'-(2-pyridylthio)-5'-deoxyadenosine
• 英文别名: S-pyridin-2-yl-5'-thio-adenosine；Pyridyl--sulfid；5'-S-Pyridin-2-yl-5'-thioadenosine；(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(pyridin-2-ylsulfanylmethyl)oxolane-3,4-diol
• CAS: 5135-38-6
• 化学式: C₁₅H₁₆N₆O₃S
• 分子量: 360.396
• InChiKey: LYDGCMAAUJUZIN-PMXXHBEXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5'-(2-pyridylthio)-5'-deoxyadenosine 在 potassium phosphate buffer 、 rh 5'-deoxy-5'-methylthioadenosine phosphorylase 作用下， 生成 、 腺嘌呤
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates

  摘要：

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.107
• 作为产物：
  描述：

  2,2'-二硫二吡啶 、 腺苷 在 三丁基膦 作用下， 以 吡啶 为溶剂， 反应 17.0h， 以96%的产率得到5'-(2-pyridylthio)-5'-deoxyadenosine
  参考文献：
  名称：

  Nakagawa, Iwao; Aki, Koichi; Hata, Tsujiaki, Journal of the Chemical Society. Perkin transactions I, 1983, # 7, p. 1315 - 1318

  摘要：

  DOI：

文献信息

• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。
• COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS
  申请人：PFIZER INC.

  公开号：EP1482977A1

  公开（公告）日：2004-12-08
• [EN] COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS<br/>[FR] POLYTHERAPIES POUR TRAITER DES CELLULES A DEFICIENCE EN METHYLTHIOADENOSINE PHOSPHORYLASE
  申请人：PFIZER

  公开号：WO2003074083A1

  公开（公告）日：2003-09-12

  The present invention is directed to combination therapies fro treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an ihibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase ('GARFT') and/or aminoinidazolecarboximide ribonucleotide formyltransferase ('AICARFT'), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or 'MTA'), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.
• Nakagawa, Iwao; Aki, Koichi; Hata, Tsujiaki, Journal of the Chemical Society. Perkin transactions I, 1983, # 7, p. 1315 - 1318
  作者：Nakagawa, Iwao、Aki, Koichi、Hata, Tsujiaki

  DOI：——

  日期：——
• Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates
  作者：Pei-Pei Kung、Luke R. Zehnder、Jerry J. Meng、Stanley W. Kupchinsky、Donald J. Skalitzky、M. Catherine Johnson、Karen A. Maegley、Anne Ekker、Leslie A. Kuhn、Peter W. Rose、Laura A. Bloom

  DOI：10.1016/j.bmcl.2005.03.107

  日期：2005.6

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.